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Pitfalls Associated With the Use of
Molecular Diagnostic Panels in the
Diagnosis of Cryptococcal Meningitis
Jane A. O’Halloran,1 Alexander Franklin,2 William Lainhart,3 Carey-Ann Burnham,3
William Powderly,1 and Erik Dubberke1
Division of Infectious Diseases, 2Department of Medicine, and 3Department of Pathology and
Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

1

We report the case of a kidney transplantation patient on
chronic immunosuppressive therapy presenting with subacute
meningitis. The final diagnosis of cryptococcal meningitis was
delayed due to 2 false-negative cryptococcal results on a molecular diagnostic panel. Caution with such platforms in suspected
cryptococcal meningitis is needed.
Keywords. cryptococcal meningitis; encephalitis; meningitis; molecular diagnostic techniques; polymerase chain
reaction.
Worldwide, Cryptococcus is the most common cause of fungal
meningitis [1]. Delayed diagnosis of cryptococcal meningitis
is associated with increased morbidity and mortality [2, 3].
Culture remains the gold standard for diagnosis of cryptococcal
disease [4]. The limitations of culture are that it can be time
consuming and labor intensive. Cryptococcal antigen (CrAg)
lateral flow assays are rapid, specific, and may be more sensitive
than culture when the burden of organism is low [4]. However,
in patients presenting with symptoms of meningo-encephalitis, the causative organism is frequently not clinically apparent,
there can be a large potential differential diagnosis requiring
consideration, and there may be limited available cerebral spinal
fluid (CSF) for testing. Efforts have been made in recent years
to develop assays that would allow testing for a wide variety
of pathogens associated with meningo-encephalitis in a short
time frame and using small volumes of CSF. The FilmArray
Meningitis/Encephalitis (ME) Panel (BioFire Diagnostics, Salt
Lake City, UT) uses multiplex polymerase chain reaction (PCR)
to test for 14 targets using just 200 µL of CSF with a reported
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hands-on time of 2 minutes and a turnaround time of approximately 1 hour [5]. As with all diagnostic tools, it is paramount
that clinicians interpret results from PCR panels such as these
in the context of the patient’s clinical presentation, and that they
are aware of any pitfalls associated with such tests. Herein we
report a case where the clinical outcome for the patient was negatively impacted by the use of a PCR panel.
CASE REPORT

A 54-year-old woman sought medical attention for a headache of 4 days’ duration, associated with nausea but without
focal neurological signs. She had undergone deceased donor
kidney transplantation for lupus nephritis–induced end-stage
kidney disease 5 years previously and was receiving tacrolimus,
mycophenolate mofetil (MMF), and prednisolone as immunosuppressive therapy. She was diagnosed with migraine and prescribed a short course of hydrocodone. She did not have a past
history of migraines. Over the proceeding month, she presented
with persistent headache twice more to her primary care provider, and on 3 occasions to the emergency department where
she underwent computed tomography and magnetic resonance
imaging (MRI) of the brain, both of which were within normal
limits.
Two months after the headache onset, the patient presented
to her local hospital with headaches, nausea and vomiting, and
fever. She was commenced on broad-spectrum antimicrobial
therapy. Her CSF revealed a white cell count (WCC) of 145
cells/cm3 (27% neutrophils, 63% lymphocytes, 10% monocytes), glucose of 36 mg/dl, and protein of 72 mg/dl. Gram stain
and routine bacterial cultures were negative. Fungal and mycobacterial cultures were not performed. A FilmArray Meningitis/
Encephalitis (ME) Panel detected human herpes virus 6 (HHV-6)
but was negative for the remaining 13 components tested for by
the panel (Escherichia coli K1, Haemophilus influenzae, Listeria
monocytogenes, Neisseria meningitidis, Streptococcus agalactiae,
Streptococcus pneumoniae, cytomegalovirus, enterovirus, herpes simplex virus 1 and 2, human parechovirus, varicella zoster
virus, and Cryptococcus neoformans/gattii). Antimicrobial therapy was discontinued, and the patient was discharged on analgesia with symptoms attributed to HHV6 infection.
In the weeks that followed, the patient continued to clinically deteriorate, developing difficulty with her gait and fecal
incontinence. New onset of abdominal pain, now 3 months
after the headache onset, prompted her to once again seek medical assessment. The patient was readmitted, and her work-up
revealed acute pancreatitis of unknown etiology, with a lipase of
18 800 units/L. At this time, MMF was held and she continued
on tacrolimus and prednisolone immunosuppression. On day
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11 of her admission, the patient became febrile to 38.6°C. Blood
cultures were obtained, and she was initiated on empiric meropenem; subsequently, linezolid and micafungin were added.
On day 19, after a fall, she was noted to be encephalopathic
with psychomotor slowing, which triggered a repeat neurological workup. A brain MRI did not reveal any acute intracranial
processes. Lumbar puncture (LP) revealed a WCC count of 320
cells/cm3 (58% neutrophils, 37% lymphocytes), a glucose of
8 mg/dl, and protein of 121 mg/dl. No opening pressure was
recorded. Again, a FilmArray ME Panel was performed, but it
was negative for all pathogens included in the panel. CSF bacterial culture was negative.
On hospital day 20, the patient was transferred to a tertiary
care academic center. On arrival, she was afebrile but remained
encephalopathic, with altered speech. She intermittently followed simple commands and had evidence of meningismus.
A high-volume (10 mL of CSF) LP was performed, and the
IMMY cryptococcal antigen lateral flow assay was positive at
a titer of 1:20. Her serum CrAg was also positive at 1:10. The
patient was initiated on liposomal amphotericin and flucytosine
for management of cryptococcal meningitis. CSF from the LP
performed prior to transfer was obtained and was also found
to be positive at a titer of 1:40. All cultures, including blood
and CSF, were negative. The patient’s symptoms improved on
liposomal amphotericin and flucytosine, and she was ultimately
discharged 3 weeks later on fluconazole.
DISCUSSION

This case highlights some important issues associated with the
use of PCR panels such as the FilmArray ME Panel in clinical practice. The clinical assay performance of the FilmArray
ME Panel was assessed in a multicenter study that examined
1560 residual CSF samples from patients undergoing lumbar
puncture at 11 sites across the United States [6]. In this study,
the results from the FilmArray ME Panel were compared with
what was considered by the study team to be an appropriate
comparator method. The comparator was CSF culture for the
bacteria and bidirectional PCR sequencing for the viruses and
fungi included in the panel. The sensitivity for Cryptococcal
neoformans/gattii was reported at 100% (1/1) and was included
in the overall assay sensitivity despite being calculated from
a single positive specimen. Specificity for Cryptococcus spp.
was reported as 99.7% (1555/1559). Of note, the comparator
method for Cryptococcus in this study was PCR and not culture
or CrAg testing. The investigators reviewed the records of the
4 patients who had positive results by the FilmArray ME Panel
but negative results by the comparator PCR and determined
that 2 were falsely negative by the comparator, and thus true
positives detected by the FilmArray ME Panel. Not included in
the published results but included in the FilmArray ME Panel
package insert were comparisons with the test results of the
clinical labs. The FilmArray ME Panel was positive for 1 of the
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8 (12.5%) specimens positive for CrAg, and positive for 2 of 3
(66.7%) that were culture positive. Of the 7 that were positive
for CrAg but negative by the FilmArray ME Panel, all patients
were on antifungals at the time of specimen collection or had a
history of Cryptococcal meningitis.
Interestingly, a smaller preclinical study of a 16-target
FilmArray ME Panel highlighted the importance of an appropriate comparator test [7]. When the 16-target assay was
performed on 342 stored CSF specimens, 8 of 14 (57%) CrAgpositive specimens were positive by the FilmArray ME panel,
with 1 specimen that was CrAg negative/FilmArray positive
also testing positive by sequencing. The false-negative results
came from specimens with relatively low CrAg titers and/
or high PCR crossing thresholds, and therefore were likely
related to low burden of disease. This may also explain why the
FilmArray ME Panel performed well in subjects with first presentations of cryptococcal meningitis in a study performed in
sub-Saharan Africa where the median quantitative culture was
8950 CFU/mL (IQR, 118–113 500 CFU/mL) [8]. Decreased
sensitivity was observed in this study on follow-up CSF specimens obtained from therapeutic lumbar puncture in patients
receiving appropriate antifungal therapy and presumably having lower fungal burdens. In those with positive cryptococcal
cultures and quantitative colony count <100 CFU/mL, the sensitivity was 50% (6/12).
In the case reported herein, the patient was treated with the
calcineurin inhibitor tacrolimus, a class of drugs known to have
in vitro antifungal activity. In solid organ transplant recipients,
tacrolimus has previously been associated with lower mortality
rates in the setting of cryptococcal infection [9]. It is therefore
possible that tacrolimus therapy may have contributed to the
lower CrAg titers in this case, and potentially to the false-negative cryptococcal result obtained on the FilmArray ME Panel,
although there are no specific data available in relation to the
latter. It is also noteworthy that while echinocandins generally
have little activity against Cryptococcus neoformans alone, in
vitro synergy between caspofungin and tacrolimus has been
reported [10].
To our knowledge, this is the first reported case of a patient
whose clinical outcome was negatively impacted by a false-negative cryptococcal PCR on the FilmArray ME panel. The patient
had known risk factors for cryptococcal meningitis with a typical clinical presentation and CSF profile, which ought to have
prompted a more thorough investigation. This case serves to
highlight to clinicians the importance of understanding the
diagnostic accuracy of tests performed in order to ensure that
they are appropriately interpreted, particularly in the setting
where a sensitive, cheap, and easily performed alternative diagnostic test exists. Compared with culture and CrAg, the sensitivity of the FilmArray ME Panel for Cryptococcus in the United
States appears to be in the mid-60% range at best. Patients with
a low burden of disease or who are already on antifungals are

more likely to have a false-negative FilmArray ME Panel for
Cryptococcus. This case also highlights the potential downside
of testing for a multitude of pathogens, several of which may
not be clinically relevant. In this case, the initial FilmArray ME
panel performed was positive for HHV6, and the patient symptoms and abnormal CSF profile were initially inappropriately
attributed to this, and possibly contributed to the delay in the
diagnosis of this patient’s cryptococcal meningitis.
In conclusion, clinicians should be aware that a negative
cryptococcal result on this platform does not rule out cryptococcal meningitis, and standard assessment with CrAg and
culture should be performed when the clinical scenario is consistent with cryptococcal infection.
Acknowledgments
Disclosures. Dr. Burnham reports grants from Cepheid, grants and
personal fees from Accelerate Diagnostics, grants from bioMerieux, grants
from Aperture Bio, grants from Theravance, personal fees from Thermo
Fisher Scientific, and personal fees from BD outside the submitted work. Dr.
Dubberke reports personal fees from Alere and personal fees from BioFire
outside the submitted work. Dr. Powderly reports grants and personal fees
from Merck Labs, grants from Astellas, and personal fees from Gilead outside the submitted work. All other authors have no reported conflicts of
interest.
Potential conflicts of interest. All authors: no reported conflicts of
interest. All authors have submitted the ICMJE Form for Disclosure of

Potential Conflicts of Interest. Conflicts that the editors consider relevant to
the content of the manuscript have been disclosed.
References
1. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIVassociated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017;
17:873–81.
2. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in
clinical features among patients with Cryptococcosis according to immune status.
PLoS One 2013; 8:e60431.
3. Aye C, Henderson A, Yu H, Norton R. Cryptococcosis—the impact of delay to
diagnosis. Clin Microbiol Infect 2016; 22:632–5.
4. Nalintya E, Kiggundu R, Meya D. Evolution of cryptococcal antigen testing: what
is new? Curr Fungal Infect Rep 2016; 2016:1–6.
5. Wootton SH, Aguilera E, Salazar L, et al. Enhancing pathogen identification in
patients with meningitis and a negative Gram stain using the BioFire FilmArray(®)
Meningitis/Encephalitis panel. Ann Clin Microbiol Antimicrob 2016; 15:26.
6. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of BioFire
FilmArray Meningitis/Encephalitis panel for detection of bacteria, viruses, and
yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016; 54:2251–61.
7. Hanson KE, Slechta ES, Killpack JA, et al. Preclinical assessment of a fully automated multiplex PCR panel for detection of central nervous system pathogens. J
Clin Microbiol 2016; 54:785–7.
8. Rhein J, Bahr NC, Hemmert AC, et al; ASTRO-CM Team. Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in
Uganda. Diagn Microbiol Infect Dis 2016; 84:268–73.
9. Singh N, Alexander BD, Lortholary O, et al; Cryptococcal Collaborative
Transplant Study Group. Cryptococcus neoformans in organ transplant recipients:
impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756–64.
10. Del Poeta M, Cruz MC, Cardenas ME, et al. Synergistic antifungal activities of
bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin
acetate (L-743 873) with calcineurin inhibitors FK506 and L-685 818 against
Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44:739–46.

BRIEF REPORT • OFID • 3

